title: Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
abstract: Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.
authors.affiliation: Department of Respiratory Medicine, Yamaguchi Prefectural Hospital, 77 Osaki, Hofu, Yamaguchi 0835-4411, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Araki
authors.forename: Isamu
authors.initials: I
authors.lastname: Okamoto
authors.forename: Ryuichiro
authors.initials: R
authors.lastname: Suto
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Ichikawa
authors.forename: Ji-ichiro
authors.initials: J
authors.lastname: Sasaki
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib